Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 114

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 114
---
 million for the six months ended June 30, 2025 was primarily due to our net loss of $8.4 million and changes in operating assets and liabilities, offset by non-cash items such as depreciation and amortization expense, stock-based compensation expense, and our operating lease right-of-use asset. Net cash used by changes in operating assets and liabilities resulted primarily from decreases of $4.2 million in our deferred grant funding liability, $0.4 million in accrued expenses, and $0.3 million in operating lease liability, offset by increases of $0.5 million in prepaid expenses, $0.2 million in accounts payable, and $0.3 million in interest payable. 

Net cash provided by operating activities of $6.1 million for the six months ended June 30, 2024 was primarily due to our net income of $6.2 million and non-cash items such as stock-based compensation expense and loss on disposal of property and equipment, offset by changes in operating assets and liabilities. Our net income for the six months ended June 30, 2024 was positively impacted by the approximately $20.4 million of net proceeds we received from the sale in April 2024 of our rights to future royalty and milestone payments and revenue to XOMA. See Note 8 "Royalty Purchase Agreements" to the accompanying condensed consolidated financial statements. Net cash used by changes in operating assets and liabilities resulted primarily from decreases of $2.8 million in our deferred grant funding liability, $1.5 million in accounts payable, and $1.4 million in accrued expenses, offset by increases of $2.6 million in prepaid expenses and $0.6 million in deposits.

Net cash used in investing activities

Net cash used in investing activities for the six months ended June 30, 2025 and 2024 related to purchases of property and equipment. 

Net cash provided by financing activities 

Net cash provided by financing activities for the six months ended June 30, 2025 consisted primarily of net proceeds from the sales of our common stock under our purchase agreement with Lincoln Park of approximately $0.9 million partially offset by payments on (i) our facility finance lease of approximately $0.5 million and (ii) insurance premium financing of approximately $0.3 million. 

43

Net cash provided by financing activities for the six months ended June 30, 2024 consisted of approximately $0.4 million in net proceeds from the sales of our common stock under